Les publications HAL NUMECAN

2015

201 publication(s) :

Articles

: 81 -
: Reply to: Van Kruiningen, H. (2015). Missing the Target to Treat in Crohn's Disease. Clinical gastroenterology and hepatology
: William J. Sandborn, Guillaume Bouguen
: Clinical Gastroenterology and Hepatology, 2015, 13 (13), pp.2381-2.
: DOI : https://doi.org/10.1016/j.cgh.2015.07.042
: Pubmed : 26247165

: 82 -
: Glucose and the risk of hypertension in first-degree relatives of patients with type 2 diabetes.
: Mohsen Janghorbani, Fabrice Bonnet, Masoud Amini
: Glucose and the risk of hypertension in first-degree relatives of patients with type 2 diabetes. Hypertension Research, 2015, 38 (5), pp.349-354.
: DOI : https://doi.org/10.1038/hr.2015.10
: Pubmed : 25693857

: 83 -
: Insuffisance ovarienne prématurée chez deux patientes présentant une délétion Xq
: Vincent Jauffret, Célia Ravel, Elouan Chérot, Christèle Dubourg, Martine Blayau, Marie-Pascale Beaumont-Epinette, Guillaume Halet, Sylvie Odent, Marc-Antoine Belaud-Rotureau, Sylvie Jaillard
: Morphologie, 2015, 20es Journées du Collège des Histologistes, Embryologistes et Cytogénéticiens - Paris 12-14 mars 2015, 99 (327), pp.168.
: DOI : https://doi.org/10.1016/j.morpho.2015.09.043

: 84 -
: Both hepatic and body iron stores are increased in dysmetabolic iron overload syndrome. A case-control study
: Caroline Jezequel, Fabrice Lainé, Bruno Laviolle, Anita Kiani, Edouard Bardou-Jacquet, Yves Deugnier
: PLoS ONE, 2015, 10 (6), pp.e0128530.
: DOI : https://doi.org/10.1371/journal.pone.0128530
: Pubmed : 26030828

: 85 -
: LKB1 and Notch Pathways Interact and Control Biliary Morphogenesis
: Pierre-Alexandre Just, Alexis Poncy, Sara Charawi, Rajae Dahmani, Massiré Traore, Typhanie Dumontet, Valérie Drouet, Florent Dumont, Hélène Gilgenkrantz, Sabine Colnot, Benoit Terris, Cédric Coulouarn, Frédéric Lemaigre, Christine Perret
: PLoS ONE, 2015,
: DOI : https://doi.org/10.1371/journal.pone.0145400.s004
: Pubmed : 26689699

: 86 -
: Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumor necrosis factor alpha agents.
: Konstantinos Karmiris, Peter Bossuyt, Dario Sorrentino, Tom Moreels, Antonella Scarcelli, Jesus Legido, Iris Dotan, Graham D Naismith, Airi Jussila, Jan C Preiss, Wolfgang Kruis, Andy C y Li, Guillaume Bouguen, Henit Yanai, Flavio Steinwurz, Konstantinos H Katsanos, Kavitha Subramaniam, Dino Tarabar, Ioannis V Zaganas, Shomron Ben-Horin
: Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumor necrosis factor alpha agents. Journal of Crohn's and Colitis, 2015, 9 (5), pp.382-389.
: DOI : https://doi.org/10.1093/ecco-jcc/jjv042
: Pubmed : 25740813

: 87 -
: The median effective analgesic dose (ED50) of ropivacaine in ultrasound-guided transversus abdominis plane block for analgesia in reversal of ileostomy: A double-blind up-down dose-finding study.
: Maria Lahlou-Casulli, Cécile Chaize-Avril, Emmanuel Pouliquen, Véronique Desfourneaux, Jean-Xavier Mazoit, Yannick Malledant, Hélène Beloeil
: The median effective analgesic dose (ED50) of ropivacaine in ultrasound-guided transversus abdominis plane block for analgesia in reversal of ileostomy: A double-blind up-down dose-finding study. European Journal of Anaesthesiology, 2015, 32 (9), pp.640-644.
: DOI : https://doi.org/10.1097/EJA.0000000000000198
: Pubmed : 25485878

: 88 -
: Le thiopental n’est pas un facteur de risque de pneumopathie tardive chez le traumatisé crânien grave. Une analyse post-hoc sur 441 traumatisés crâniens graves
: Sigismond Lasocki, Karim Asehnoune, Philippe Seguin, Antoine Roquilly, Olivier Mimoz, Claire Dahyot, Yannick Mallédant, Jean-François Hamel
: Anesthésie & Réanimation, 2015, 1S1 congrès SFAR 2015, 1, Supplement 1, pp.A6.
: DOI : https://doi.org/10.1016/j.anrea.2015.07.009

: 89 -
: Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
: Eric Lawitz, Edward Gane, Brian Pearlman, E. Tam, Wayne Ghesquiere, Dominique Guyader, Laurent Alric, Jean-Pierre Bronowicki, Laura Lester, William Sievert, Reem Ghalib, Luis Balart, Fredrik Sund, Martin Lagging, Frank Dutko, Melissa Shaughnessy, Peggy Hwang, Anita y M Howe, Janice Wahl, Michael Robertson, Eliav Barr, Barbara Haber
: Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. The Lancet, 2015, 385 (9973), pp.1075-86.
: DOI : https://doi.org/10.1016/S0140-6736(14)61795-5
: Pubmed : 25467591

: 90 -
: Les anesthésiques locaux stimulent l’apoptose des cellules de carcinome hépatocellulaire
: Grégoire Le Gac, Cédric Coulouarn, Bruno Clément, Gaelle Angenard, Isabelle Cannie, Hélène Beloeil
: Anesthésie & Réanimation, 2015, 1S1 congrès SFAR 2015, 1, Supplement 1, pp.A197--A198.
: DOI : https://doi.org/10.1016/j.anrea.2015.07.302